Clinical trial
Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy…
NCT00166322 · Ludwig-Maximilians - University of Munich, Other · Completed
Key facts
| NCT number | NCT00166322 |
|---|---|
| Title | Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects |
| Lead sponsor | Ludwig-Maximilians - University of Munich, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Procedure |
| Interventions | IBZM-SPECT (bolus and constant infusion paradigm) |
| Enrollment | 35 |
| Start date | Jan 1, 2004 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 14, 2005 |
| Last update posted | May 7, 2008 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: